南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

光遗传学控制免疫治疗设计细胞用于术后肿瘤免疫治疗研究

Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy

Yu Yuanhuan, Wu Xin, Wang Meiyan, Liu Wenjing, Zhang Li, Zhang Ying, Hu Zhilin, Zhou Xuantong, Jiang Wenzheng, Zou Qiang, Cai Fengfeng, Ye Haifeng

Journal:Nature Communications

IF:17.69

DOI:10.1038/s41467-022-33891-9

PMID:36289204

Published:2022-10-26

research field:肿瘤学药理学生物医学工程治疗学

Abstract

Surgical resection is the main treatment option for most solid tumors, yet cancer recurrence after surgical resection remains a significant challenge in cancer therapy. Recent advances in cancer immunotherapy are enabling radical cures for many tumor patients, but these technologies remain challenging to apply because of side effects related to uncontrollable immune system activation. Here, we develop far-red light-controlled immunomodulatory engineered cells (FLICs) that we load into a hydrogel scaffold, enabling the precise optogenetic control of cytokines release (IFN-β, TNF-α, and IL-12) upon illumination. Experiments with a B16F10 melanoma resection mouse model show that FLICs-loaded hydrogel implants placed at the surgical wound site achieve sustainable release of immunomodulatory cytokines, leading to prevention of tumor recurrence and increased animal survival. Moreover, the FLICs-loaded hydrogel implants elicit long-term immunological memory that prevents against tumor recurrence. Our findings illustrate that this optogenetic perioperative immunotherapy with FLICs-loaded hydrogel implants offers a safe treatment option for solid tumors based on activating host innate and adaptive immune systems to inhibit tumor recurrence after surgery. Beyond extending the optogenetics toolbox for immunotherapy, we envision that our optogenetic-controlled living cell factory platform could be deployed for other biomedical contexts requiring precision induction of bio-therapeutic dosage.

本文使用的Yeasen产品

购物车
客服
转染试用